Metabolomic Effects of Hormone Therapy and Associations With Coronary Heart Disease Among Postmenopausal Women

  title={Metabolomic Effects of Hormone Therapy and Associations With Coronary Heart Disease Among Postmenopausal Women},
  author={Raji Balasubramanian and Olga V Demler and Marta Guasch-Ferr{\'e} and Nina P Paynter and Ryan Sheehan and Simin Liu and JoAnn E. Manson and Jordi Salas-Salvad{\'o} and Miguel Angel Mart{\'i}nez-Gonz{\'a}lez and Frank B. Hu and Clary B. Clish and Kathryn M. Rexrode},
  journal={Circulation: Genomic and Precision Medicine},
Supplemental Digital Content is available in the text. Background: In the WHI-HT trials (Women’s Health Initiative Hormone Therapy), treatment with oral conjugated equine estrogens and medroxyprogesterone acetate (CEE+MPA) resulted in increased risk of coronary heart disease (CHD), whereas oral conjugated equine estrogens (CEE) did not. Methods: Four hundred eighty-one metabolites were measured at baseline and at 1-year in 503 and 431 participants in the WHI CEE and CEE+MPA trials, respectively… Expand

Figures and Tables from this paper


Metabolic Predictors of Incident Coronary Heart Disease in Women
These data replicate known metabolite predictors, identify novel markers, and support the relationship between lipid oxidation and subsequent CHD. Expand
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD. Expand
Serum metabolomic profiles associated with postmenopausal hormone use
It is suggested that postmenopausal hormone use influences metabolic pathways linked to a variety of cellular processes, including the regulation of metabolism and stress responses, energy production, and inflammation. Expand
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.
Whether the effects of hormone therapy on risk of cardiovascular disease vary by age or years since menopause began is explored to explore and women who initiated hormone therapy closer toMenopause tended to have reduced CHD risk compared with the increase inCHD risk among women more distant from menopausal symptoms. Expand
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
The use of conjugated equine estrogen (CEE) increases the risk of stroke, decreases therisk of hip fracture, and does not affect CHD incidence in postmenopausal women with prior hysterectomy over an average of 6.8 years, indicating no overall benefit. Expand
Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women
Circulating plasma BCAAs were positively associated with incident CVD in women and impaired BCAA metabolism may capture the long-term risk of the common cause underlying T2D and CVD. Expand
Metabolic Signatures of Insulin Resistance in 7,098 Young Adults
Metabolite associations with insulin resistance were studied in young Finns to elucidate underlying metabolic pathways and reflect the degree of insulin resistance evidenced in young, normoglycemic adults with sex-specific fingerprints. Expand
Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
Most risks and benefits dissipated postintervention, although some elevation in breast cancer risk persisted during cumulative follow-up and the 2 WHI hormone therapy trials do not support use of this therapy. Expand
Plasma Branched-Chain Amino Acids and Incident Cardiovascular Disease in the PREDIMED Trial.
Higher concentrations of baseline BCAAs were associated with increased risk of CVD, especially stroke, in a high cardiovascular risk population in a case-cohort study within the Prevención con Dieta Mediterránea. Expand
Sugar-Sweetened Beverages and Cardiometabolic Health: An Update of the Evidence
Conclusive evidence from cohort studies and trials on risk factors support an etiologic role of SSB in relation to weight gain and risk of T2D and CHD, independent of adiposity. Expand